Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Gastrointestinal Stromal Tumors × ripretinib × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 9 Observational 2 Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1 Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

ripretinib 1 regorafenib 1 avapritinib 1 Sunitinib 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04148092 2020-05-29

Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST

Deciphera Pharmaceuticals, LLC

Approved for marketing

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡